Boundless Bio, Inc. Price & Performance (BOLD)

Zachary Hornby, CEO of Boundless Bio, highlighted the company's innovative cancer therapies targeting extrachromosomal DNA during a fireside chat at the Leerink Global Healthcare Conference on March 12. The firm is advancing its leading candidate, BBI-355, currently in Phase 1/2 trials, aiming to address oncogene amplified cancers.12

Recent layoffs across the biotech industry include cuts by Ryvu Therapeutics, Kojin Therapeutics, and Affini-T Therapeutics. Companies are responding to funding challenges and pipeline adjustments. Ryvu aims to extend its cash runway, Kojin is shutting down, and Affini-T is focusing resources on solid tumor therapies.3

Several biopharma companies, including Turnstone Biologics and Barinthus Biotherapeutics, announced layoffs to conserve resources and refocus pipelines. Turnstone is halting its TIDAL-01 program, while Barinthus is pausing hepatitis B drug development. These moves reflect broader industry challenges and efforts to maximize financial sustainability.3